Head-to-head evidence
BIIB122 / DNL151 (LRRK2 inhibitor) vs NEU-411
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: LRRK2 · full Parkinson's Disease pipeline
BIIB122 / DNL151 (LRRK2 inhibitor)
Developed by Biogen under a licence from Denali Therapeutics
NCT05418673 · Phase 3 · terminated
Although the trial was designed as a randomized, blinded, placebo-controlled study, it enrolled only 7 participants and was stopped early by the sponsor before anyone completed it. Because of this, no data are reported for the primary measure of disease progression, so the trial does not provide usable evidence on whether the drug works.
Next expected readout: March 2027 · NCT06602193 (registry estimate)
NEU-411
Developed by Neuron23
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06680830 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BIIB122 / DNL151 (LRRK2 inhibitor)'s landscape · NEU-411's landscape